TABLE 4.
The research progress of SARS-CoV-2 nucleocapsid protein vaccine.
| Vaccine name | Team | Vaccine type | Vector | Administration route | Dose | Animal experiment | Challenge trials | References |
| Tri: ChAd | Sam Afkhami | Viral Vectored Vaccine | ChAd | IM, IN | 1 | Mouse | B.1.1.7, B.1.351 | Afkhami et al., 2022 |
| Ad5-N | Tanushree Dangi | Viral Vectored Vaccine | Ad | IM | 1 | Mouse | WA1/2020 | Dangi et al., 2021 |
| Ad5-N | Jia He | Viral Vectored Vaccine | Ad | IN | 2 | Mouse | - | He et al., 2021 |
| COH04S1 | Flavia Chiuppesi | Viral Vectored Vaccine | MVA | IM, IN | 1, 2 | Hamster, NHP | WA1/2020 | Chiuppesi et al., 2022 |
| MVA/SdFCS-N | Nanda Kishore Routhu | Viral Vectored Vaccine | MVA | IM, BU, SL | 2 | Rhesus macaque, Mouse | WA-1/2020, β, delta (B.1.617.2) | Routhu et al., 2022 |
| rACAM2000SN | YvonDeschambault | Viral Vectored Vaccine | VACV | IM | 1 | Hamster | ON-VIDO-01/2020 | Deschambault et al., 2022 |
| mRNA-S + N | Renee L. Hajnik | RNA vaccine | LNPs | IM, IN | 2 | Mouse, Hamster | MA-SARS-CoV-2, Delta, and Omicron | Hajnik et al., 2022 |
| SpiN | Julia T. Castro | Recombinant Protein Vaccine | - | IM | 2 | Mouse, Hamster | BRA/SP02/2020, Delta, and Omicron | Castro et al., 2022 |
| RBD-P2/N | So-Hee Hong | Recombinant Protein Vaccine | - | IM | 2 | Mouse, Rat, NHP | SARS-CoV-2 | Hong et al., 2021 |
MVA, modified vaccinia Ankara; VACV, vaccinia virus; Ad, adenovirus; LNPs, lipid nanoparticles; IM, intramuscular; IN, intranasal; BU, buccal; SL, sublingual; NHP, non-human primate; Challenge trials: This column is the strain information of the challenge trials.